<DOC>
	<DOCNO>NCT01810315</DOCNO>
	<brief_summary>Purpose study ass tenofovir ( TFV ) PK PD endpoint , cervicovaginal safety parameter , susceptibility HIV-1 infection , objective measure vaginal applicator use premenopausal postmenopausal woman .</brief_summary>
	<brief_title>Influence Reproductive Cycle Menopause HIV-1 Infection TFV Gel Activity</brief_title>
	<detailed_description>Premenopausal woman : Baseline blood genital sample take follicular luteal phase ( visit 2 3 ) . The participant give TFV gel instruct insert two dos , separate 2 hour , return clinic 3 hour second insertion blood genital sample ( visit 4/4a 5/5a ) . Postmenopausal woman : Premenopausal woman : Baseline blood genital sample take ( visit 2 ) . The participant give TFV gel instruct insert two dos , separate 2 hour , return clinic 3 hour second insertion blood genital sample ( visit 3/3a ) . Estradiol cream distribute visit 4 . Post estradiol blood genital sample take Visit 5 . The participant give TFV gel instruct insert 2 dos , continue use estradiol cream . Post TFV gel estradiol cream blood genital sample take ( visit 6/6a ) .</detailed_description>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>All volunteer In good healthsignificant systemic disease Not risk STI , meaning : In monogamous heterosexual sex relationship least last four month partner know HIV positive know risk STIs OR sexually abstinent Willing able comply study procedure Normal Pap smear ( write report ) past year . Premenopausal volunteer 21to45 year age Not risk pregnancy , meaning : Regular menstrual cycle ( every 24 35 day ) Luteal phase P level great equal 3 ng/ml Postmenopausal volunteer 4689 year age OR ovaries remove least 30 day prior Visit 1 No menstrual periods/vaginal bleeding past 12 month OR ovary remove least 30 day prior Visit 1 FSH level great equal 20 MIU/ml All volunteer Clinically significant history abnormal Pap smear past year Surgery biopsy vagina cervix within 30 day Current STI low genital tract infection Current use chronic immunosuppressant Current presence vulvar , anal and/or vaginal genital wart Current tobacco use amount History sensitivity/allergy component study product , topical anesthetic , allergy silver nitrate and/or Monsel 's solution Known bleeding disorder could lead prolonged continuous bleed Grade 1 high laboratory abnormality , per August 2009 update DAIDS Table Grading Severity Adverse Events Systemic use last two week anticipate use study follow : corticosteroid , antibiotic , anticoagulant drug know prolong bleed and/or clotting , antifungal , antiviral antiretrovirals . Investigator discretion Current participation drug device study Premenopausal woman Use DMPA last six month Use hormonal contraceptive method without 2 subsequent , normal menses since stop hormonal contraceptive Current use copper IUD Currently pregnant pregnancy within past 3 month Currently breastfeeding/having breastfed infant last 2 month Postmenopausal woman Use hormonal medication past 30 day Contraindications vaginal estrogen cream</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>